Australian-owned optical lens and equipment supplier Opticare has two new spectacle lens designs adopting the principle of peripheral retinal defocus for myopia management.
With the oft-quoted prediction of half the world’s population being myopic by 2050 posing a major challenge to the optical industry, researchers are racing to develop effective strategies to slow or delay myopia progression.
Simultaneously, optometrists are charged with educating their young at-risk patients and their parents about the consequences of uncontrolled progressive myopia, noting that myopia is not simply a blurry inconvenience but an ocular health risk with significant visual consequences.
MyoEase and MyOnic
Opticare says its two new spectacle lens developments provide further options for effective myopia management. Like other spectacle lens designs, the MyoEase and MyOnic lenses are based on the principle of peripheral retinal defocus while providing a sharp central zone to correct distance vision.
According to the company, the MyoEase lens is designed with a mid-peripheral ring of high-precision, micro-transparent pinholes. This creates a zone of peripheral optical defocus, effectively retarding axial elongation in a myopic eye.
Meanwhile, the MyOnic myopia control lens contains a 10mm central single vision zone surrounded by a mid-peripheral positive defocus ring. A constant power zone at the very periphery of the lens enables easier adaptation during ocular movements, Opticare stated.
“Both groundbreaking lens designs are available in a range of material indices and lens coatings. MyoEase is suitable for myopia up to -16.00D and MyOnic up to -20.00D, enabling effective management of the vast majority of your young myopic patients,” the company said.
For more information about MyoEase and MyOnic lenses, visit www.opticare.com.au, call 1800 251 852, or email info@opticare.com.au.
